Exhibit 10.1 


 


NexGel, Inc.


Up to $2,700,000 Shares of Common Stock


 


Equity Distribution Agreement


April 13, 2022


 


Maxim Group LLC

300 Park Avenue, 16th Floor

New York, New York 10022


 


Ladies and Gentlemen:


 


NexGel, Inc., a Delaware corporation
(the "Company"), proposes to issue and sell through Maxim Group LLC (the "Agent"), as
exclusive sales agent, shares of common stock, par value $0.001 per share ("Common Stock"), of the Company (the
 "Shares") having an aggregate offering price of up to $2,700,000 on terms set forth herein. The Shares consist
entirely of authorized but unissued shares of Common Stock to be issued and sold by the Company.


 


The Company hereby confirms
its agreement with the Agent (this "Agreement") with respect to the sale of the Shares.


 


		1.	Representations and Warranties of the Company.



 


(a)       The
Company represents and warrants to, and agrees with, the Agent as follows:


 


(i)                
The Company has filed, or shall file, in accordance with the provisions of the Securities Act of 1933, as amended and the
rules and regulations thereunder (the "Rules and Regulations"
and collectively with the Securities Act of 1933, the "Securities Act"), with the Securities and Exchange
Commission (the “Commission”), a registration statement on Form S-3, including a base prospectus, relating to
certain securities including the Shares to be issued from time to time by the Company, and which incorporates by reference documents that
the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended and the rules
and regulations thereunder (the “Exchange Act”). The Company has prepared a Prospectus Supplement to the Base
Prospectus included as part of such registration statement specifically relating to the Shares. The Company will furnish to the Agent,
for use by the Agent, copies of the base prospectus included as part of such registration statement, as supplemented by the Prospectus
Supplement, relating to the Shares.. Except where the context otherwise requires,
 "Registration Statement," as used herein, means the registration statement referred to herein, as amended at the
time of such registration statement's effectiveness for purposes of Section 11 of the Securities Act, as such section applies to the Agent,
including (1) all documents filed as a part thereof or incorporated or deemed to be incorporated by reference therein, (2) any information
contained or incorporated by reference in a prospectus filed with the Commission pursuant to Rule 424(b) under the Securities Act, to
the extent such information is deemed, pursuant to Rule 430B or Rule 430C under the Securities Act, to be part of the registration statement
at such time, and (3) any registration statement filed to register the offer and sale of Shares pursuant to Rule 462(b) under the Securities
Act (the "462(b) Registration Statement"). Except where the context otherwise requires, "Base Prospectus,"
as used herein, means the base prospectus filed as part of the Registration Statement, together with any amendments or supplements thereto
as of the date of this Agreement. Except where the context otherwise requires, "Prospectus Supplement," as used
herein, means the most recent prospectus relating to the Shares, filed or to be filed by the Company with the Commission as part of the
Base Prospectus pursuant to Rule 424(b) under the Securities Act and in accordance with the terms of this Agreement. Except where the
context otherwise requires, "Prospectus," as used herein, means the Prospectus Supplement together with the Base
Prospectus attached to or used with the Prospectus Supplement, as may be amended or supplemented from time to time. "Permitted
Free Writing Prospectus," as used herein, means the documents, if any, listed on Schedule A attached hereto and, after
the date hereof, any "issuer free writing prospectus" as defined in Rule 433 of the Securities Act, that is expressly agreed
to by the Company and the Agent in writing to be a Permitted Free Writing Prospectus. Any reference herein to the Registration Statement,
the Base Prospectus, the Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus shall be deemed to refer to and
include the documents, if any, incorporated by reference, or deemed to be incorporated by reference, therein pursuant to Item 12 of Form
S-3 (the "Incorporated Documents"), including, unless the context otherwise requires, the documents, if any, filed
as exhibits to such Incorporated Documents. For purposes of this Agreement, all references to the Registration Statement, the Rule 462(b)
Registration Statement, the Base Prospectus, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to
include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System ("EDGAR").
All references in this Agreement to financial statements and schedules and other information which is "described," "contained,"
 "included" or "stated" in the Registration Statement, the Base Prospectus, the Prospectus or any Permitted Free Writing
Prospectus (or other references of like import) shall be deemed to mean and include all such financial statements and schedules and other
information which is incorporated by reference in or otherwise deemed by the Rules and Regulations to be a part of or included in the
Registration Statement, the Base Prospectus, the Prospectus or Permitted Free Writing Prospectus as the case may be. Any reference herein
to the terms "amend," "amendment" or "supplement" with respect
to the Registration Statement, any Base Prospectus, the Prospectus, the Prospectus Supplement or any Permitted Free Writing Prospectus
shall be deemed to refer to and include the filing of any document under the Securities Exchange Act of 1934, as amended, and the rules
and regulations thereunder (collectively, the "Exchange Act") on or after the initial effective date of the Registration
Statement, or the date of such Base Prospectus, the Prospectus, the Prospectus Supplement or such Permitted Free Writing Prospectus, if
any, as the case may be, and incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3. "Time
of Sale" means each time a Share is purchased pursuant to this Agreement.


 






     


     


    

 


(ii)             
(A)The
Registration Statement complies as of the date hereof, and will comply upon the effectiveness of the Registration Statement and any amendment
thereto and at each Time of Sale and each Settlement Date (as applicable), in all material respects, with the requirements of the Securities
Act; at all times during which a prospectus is required by the Securities Act to be delivered (whether physically or through compliance
with Rule 172 under the Securities Act or any similar rule) in connection with any sale of Shares (the "Prospectus Delivery
Period"), the Registration Statement, as may be amended, will comply, in all material respects, with the requirements of
the Securities Act; the conditions to the use of Form S-3 in connection with the offering and sale of the Shares as contemplated hereby
(the "Offering") have been satisfied, subject to the limitations required by General Instruction I.B.6 of Form
S-3, if applicable; the Registration Statement meets, and the Offering complies with, the requirements of Rule 415 under the Securities
Act (including, without limitation, Rule 415(a)(5)); the Registration Statement did not, as of the date hereof, and will not, as of the
effective date of the Registration Statement or any amendment thereto, at each Time of Sale, if any, and at all times during a Prospectus
Delivery Period, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein not misleading.


 


(B)       The
Prospectus, as of the date of the Prospectus Supplement, as of the date hereof (if filed with the Commission on or prior to the date hereof),
at each Settlement Date and Time of Sale (as applicable), and at all times during a Prospectus Delivery Period, complied, complies or
will comply, in all material respects, with the requirements of the Securities Act; and the Prospectus, and each supplement thereto, as
of their respective dates, at each Settlement Date or Time of Sale (as applicable), and at all times during a Prospectus Delivery Period,
did not and will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading.


 






     


     


    

 


(C)
       Each Permitted Free Writing Prospectus, if any, as of its
date and as of each Settlement Date and Time of Sale (as applicable), and at all times during a Prospectus Delivery Period (when taken
together with the Prospectus at such time) will not include an untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.


 


The representations and warranties set
forth in subparagraphs (A), (B) and (C) above shall not apply to any statement contained in the Registration Statement, the Base Prospectus,
the Prospectus or any Permitted Free Writing Prospectus in reliance upon and in conformity with information concerning the Agent that
is furnished in writing by or on behalf of the Agent expressly for use in the Registration Statement, the Base Prospectus, the Prospectus
or such Permitted Free Writing Prospectus, if any, it being understood and agreed that only such information furnished by the Agent as
of the date hereof consists of the information described in Section 5(b)(ii).


 


(iii)           
 Prior to the execution of this Agreement, the Company has not,
directly or indirectly, offered or sold any Shares by means of any "prospectus" (within the meaning of the Securities Act) or
used any "prospectus" (within the meaning of the Securities Act) in connection with the Offering, in each case other than the
Base Prospectus or any Permitted Free Writing Prospectus; the Company has not, directly or indirectly, prepared, used or referred to any
Permitted Free Writing Prospectus except in compliance with Rules 164 and 433 under the Securities Act; assuming that a Permitted Free
Writing Prospectus, if any, is sent or given after the Registration Statement was filed with the Commission (and after such Permitted
Free Writing Prospectus, if any, was, if required pursuant to Rule 433(d) under the Securities Act, filed with the Commission), the Company
will satisfy the provisions of Rule 164 or Rule 433 necessary for the use of a free writing prospectus (as defined in Rule 405) in connection
with the Offering; the conditions set forth in one or more of subclauses (i) through (iv), inclusive, of Rule 433(b)(1) under the Securities
Act are satisfied, and the registration statement relating to the Offering, as initially filed with the Commission, includes a prospectus
that, other than by reason of Rule 433 or Rule 431 under the Securities Act, satisfies the requirements of Section 10 of the Securities
Act; neither the Company nor the Agent is disqualified, by reason of subsection (f) or (g) of Rule 164 under the Securities Act, from
using, in connection with the Offering, "free writing prospectuses" (as defined in Rule 405 under the Securities Act) pursuant
to Rules 164 and 433 under the Securities Act; the Company is not an "ineligible issuer" (as defined in Rule 405 under the Securities
Act) as of the eligibility determination date for purposes of Rules 164 and 433 under the Securities Act with respect to the offering
of the Shares contemplated by the Registration Statement; the parties hereto agree and understand that the content of any and all "road
shows" (as defined in Rule 433 under the Securities Act) related to the Offering is solely the property of the Company.


 






     


     


    

 


(iv)            
Each Permitted Free Writing Prospectus, as of its issue date, each
Time of Sale and each Settlement Date occurring after such issue date and at all subsequent times through the Prospectus Delivery Period
(as defined below) or until any earlier date that the Company notified or notifies the Agent as described in Section 3(c)(iii),
did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the
Registration Statement, any Base Prospectus or the Prospectus. The foregoing sentence does not apply to statements in or omissions from
any Permitted Free Writing Prospectus based upon and in conformity with written information furnished to the Company by the Agent specifically
for use therein, it being understood and agreed that the only such information furnished by the Agent as of the date hereof consists of
the information described in Section 5(b) (ii).


 


(v)              
The financial statements, including the notes thereto, and the
supporting schedules incorporated by reference in the Registration Statement and the Prospectus comply in all material respects with the
requirements of the Securities Act, the Exchange Act and the Rules and Regulations, and present fairly the financial condition of the
Company and its subsidiaries (as identified in the Registration Statement and Prospectus, the “Subsidiaries”)
and financial position as of the dates indicated and the cash flows and results of operations for the periods specified of the Company.
Except as otherwise stated in the Registration Statement and the Prospectus, said financial statements have been prepared in conformity
with United States generally accepted accounting principles ("GAAP") applied on a consistent basis throughout
the periods involved. Any selected financial data and summary financial information included in the documents in the Registration Statement
and in the Prospectus constitute or will constitute a fair summary of the information purported to be summarized and have been compiled
on a basis consistent with that of the audited financial statements included in the Registration Statement. No other financial statements
or supporting schedules are required to be included or incorporated by reference in the Registration Statement or the Prospectus. All
disclosures, if any, contained in the Registration Statement or the Prospectus or incorporated by reference therein regarding “non-GAAP
financial measures” (as such term is defined by the applicable rules and regulations of the Commission) comply, in all material
respects, with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act to the extent applicable. The other
financial information included in the Registration Statement and the Prospectus present fairly the information included therein and have
been prepared on a basis consistent with that of the financial statements that are included in the Registration Statement and the Prospectus
and the books and records of the Company. 


 






     


     


    

 


(vi)            
The Company and each of its Subsidiaries has been duly incorporated
and validly exists as a corporation in good standing under the laws of its jurisdiction of incorporation. The Company and each of its
Subsidiaries has all requisite corporate power and authority to own, lease and operate its respective properties and carry on its business
as it is currently being conducted and as described in the Registration Statement and the Prospectus. The Company and each of its Subsidiaries
is duly qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the character or location
of its properties (owned, leased or licensed) or the nature or conduct of its business makes such qualification necessary, except, in
each case, for those failures to be so qualified or in good standing which (individually or in the aggregate) would not reasonably be
expected to have a Material Adverse Effect (as defined below).


 


(vii)         
All of the issued shares of capital stock of the Company have been
duly authorized and validly issued and are fully paid and nonassessable, have been issued in compliance in all material respects with
all applicable federal and state securities laws and none of those shares was issued in violation of any preemptive rights, rights of
first refusal or other similar rights to the extent any such rights were not waived; the Shares have been duly authorized and, when issued
and delivered against payment therefor as provided in this Agreement, will be validly issued, fully paid and non-assessable, and the issuance
of the Shares is not subject to any preemptive rights, rights of first refusal or other similar rights that have not heretofore been waived
(with copies of such waivers provided or made available to the Agent). The Shares conform in all material respects to the descriptions
thereof contained in the Registration Statement and the Prospectus under the heading "Description of Capital Stock."


 


(viii)       
Turner, Stone & Company, L.L.P. (the "Auditor"),
whose reports relating to the Company are incorporated by reference into the Registration Statement and the Prospectus, is an independent
registered public accounting firm as required by the Securities Act, the Exchange Act and the Rules and Regulations and the Public Company
Accounting Oversight Board (the "PCAOB"). To the Company's knowledge, the Auditor is not in violation of the auditor
independence requirements of the Sarbanes-Oxley Act of 2002 ("Sarbanes-Oxley") as such requirements pertain to
the Auditor's relationship with the Company. Except as disclosed in the Registration Statement and the Prospectus, and except for any
such non-audit services that were pre-approved by the Audit Committee of the Company's Board of Directors in accordance with Sections
10A(h) and (i) of the Exchange Act, the Auditor has not, during the periods covered by the financial statements included in the Registration
Statement and the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.


 






     


     


    

 


(ix)            
Subsequent to the respective dates as of which information is presented
in the Registration Statement and the Prospectus, and except as disclosed in the Registration Statement and the Prospectus: (i) the Company
(including its Subsidiaries) has not declared, paid or made any dividends or other distributions of any kind on or in respect of its capital
stock, and (ii) there has been no material adverse change or, to the Company's knowledge, any development which could reasonably be expected
to result in a material adverse change in the future, whether or not arising from transactions in the ordinary course of business, in
or affecting: (A) the business, condition (financial or otherwise), results of operations, stockholders' equity, properties or prospects
of the Company or its Subsidiaries; (B) the long-term debt or capital stock of the Company or its Subsidiaries; or (C) the Offering or
consummation of any of the other transactions contemplated by this Agreement, the Registration Statement and the Prospectus (a "Material
Adverse Effect"). Since the date of the latest balance sheet included in the Registration Statement and the Prospectus, the
Company (including its Subsidiaries) has not incurred or undertaken any liabilities or obligations, whether direct or indirect, liquidated
or contingent, matured or unmatured, or entered into any transactions, including any acquisition or disposition of any business or asset,
which are material to the Company, except (I) for liabilities, obligations and transactions which are disclosed in the Registration Statement
and the Prospectus and (II) as would not be reasonably expected (individually or in the aggregate) to result in a Material Adverse Effect.


 


(x)              
There are no statutes, regulations, contracts or documents that are required to be described in the Registration Statement
and the Prospectus or to be filed as exhibits to the Registration Statement by the Securities Act that have not been so described or filed.


 


(xi)            
Neither the Company nor any of its Subsidiaries is: (i) in violation
of its certificate of incorporation or bylaws or other organizational documents, (ii) in default under any indenture, mortgage, deed of
trust, loan agreement or other agreement or instrument to which it is a party or by which it is bound or to which any of its property
or assets is subject; and no event has occurred which, with notice or lapse of time or both, would constitute a default under or result
in the creation or imposition of any lien, security interest, charge or other encumbrance (a "Lien") upon any
of its property or assets pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which
it is a party or by which it is bound or to which any of its property or assets is subject, or (iii) in violation in any respect of any
applicable law, rule, regulation, ordinance, directive, judgment, decree or order of any judicial, regulatory or other legal or governmental
agency or body, foreign or domestic, except, in the case of subsections (ii) and (iii) above, for such violations, defaults or Liens which
(individually or in the aggregate) would not reasonably be expected to have a Material Adverse Effect.


 






     


     


    

 


(xii)         
The Company has all requisite corporate power and authority to
execute and deliver this Agreement and all other agreements, documents, certificates and instruments required to be delivered pursuant
to this Agreement. The Company's execution, delivery and performance under this Agreement and each of the transactions contemplated hereby
have been duly authorized by all necessary corporate action. This Agreement has been duly and validly executed and delivered by the Company
and constitutes the legal, valid and binding obligation of the Company and is enforceable against the Company in accordance with its terms,
except (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors' rights
generally; (ii) as enforceability of any indemnification or contribution provision may be limited under federal and state securities laws;
and (iii) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses
and to the discretion of the court before which any proceeding therefor may be brought.


 


(xiii)       
The execution, delivery and performance of this Agreement and all
other agreements, documents, certificates and instruments required to be delivered pursuant to this Agreement and the consummation of
the transactions contemplated hereby do not and will not: (i) conflict with, require consent under or result in a breach of any of the
terms and provisions of, or constitute a default (or an event which with notice or lapse of time, or both, would constitute a default)
under, or result in the creation or imposition of any Lien upon any property or assets of the Company pursuant to, any indenture, mortgage,
deed of trust, loan agreement or other agreement, instrument, franchise, license or permit to which the Company is a party or by which
the Company or any of its properties, operations or assets may be bound, (ii) violate or conflict with any provision of the certificate
of incorporation, bylaws or other organizational documents of the Company, or (iii) violate or conflict with any applicable law, rule,
regulation, ordinance, directive, judgment, decree or order of any judicial, regulatory or other legal or governmental agency or body,
domestic or foreign, except in the case of subsections (i) and (iii) for any default, conflict, violation or Lien for which the Company
has received a waiver or that would not reasonably be expected to result in a Material Adverse Effect.


 






     


     


    

 


(xiv)        
Except as disclosed in the Registration Statement and the Prospectus,
the Company and each of its Subsidiaries has all consents, approvals, authorizations, orders, registrations, qualifications, licenses,
filings, grants, certificates and permits of, with and from all judicial, regulatory and other legal or governmental agencies, self-regulatory
agencies, authorities and bodies and all third parties, foreign and domestic, including, without limitation, the U.S. Food and Drug Administration
("FDA") or equivalent in non-U.S. jurisdictions (collectively, the "Consents"), to own,
lease and operate its properties and conduct its business as it is now being conducted and as disclosed in the Registration Statement
and the Prospectus, and each such Consent is valid and in full force and effect, except which (individually or in the aggregate), in each
such case, would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has received
notice of any investigation or proceedings which results in or, if decided adversely to the Company or such Subsidiary, could reasonably
be expected to result in, the revocation of, or imposition of a restriction on, any Consent, except such restriction or revocation of
such Consent which (individually or in the aggregate) would not reasonably be expected to have a Material Adverse Effect. No Consent contains
any material restriction not adequately disclosed in the Registration Statement and the Prospectus.


 


(xv)          
The Company and each of its Subsidiaries are in compliance with
all applicable laws, rules, regulations, ordinances, directives, judgments, decrees and orders, foreign and domestic, except for any non-compliance
the consequences of which would not have a Material Adverse Effect.


 


(xvi)        
The Company hereby agrees to use reasonable best efforts to obtain
approval of the Shares for listing on the NASDAQ Capital Market, subject to official notice of issuance (the "Exchange").
The Company has taken no action designed to, or likely to have the effect of, delisting the Shares nor, except as disclosed in the Registration
Statement and the Prospectus, has the Company received any notification that the Exchange is contemplating terminating such listing.


 


(xvii)     
No consents, approvals, authorizations, orders, registrations,
qualifications, licenses, filings, grants, certifications and permits of, with or from any judicial, regulatory or other legal or governmental
agency or body or any third party, foreign or domestic is required for the execution, delivery and performance of this Agreement or consummation
of each of the transactions contemplated by this Agreement, including the issuance, sale and delivery of the Shares to be issued, sold
and delivered hereunder, except (i) such as may have previously been obtained (with copies of such consents provided to the Agent), each
of which is in full force and effect as of the date hereof, (ii) the registration under the Securities Act of the Shares, which has become
effective and which remains in full force and effect as of the date hereof, (iii) such consents as may be required under state securities
or blue sky laws or the bylaws and rules of the Exchange, and (iv) by the Financial Industry Regulatory Authority, Inc. ("FINRA")
in connection with the purchase and distribution of the Shares by the Agent.


 






     


     


    

 


(xviii)   
Except as disclosed in the Registration Statement and the Prospectus,
there is no judicial, regulatory, arbitral or other legal or governmental proceeding or other litigation or arbitration, domestic or foreign,
pending to which the Company or any of its Subsidiaries is a party or of which any property, operations or assets of the Company or its
Subsidiaries is the subject which (i) individually or in the aggregate, if determined adversely to the Company or applicable Subsidiary
would reasonably be expected to have a Material Adverse Effect, or (ii) is reasonably likely to materially and adversely affect the consummation
of the transactions contemplated in this Agreement or the performance by the Company of its obligations hereunder. To the Company's knowledge,
no such proceeding, litigation or arbitration is threatened or contemplated against the Company or its Subsidiaries.


 


(xix)        
The statistical, industry-related and market-related data included
in the Registration Statement and the Prospectus are based on or derived from sources which the Company reasonably and in good faith believes
are reliable and accurate, and the Company has obtained the written consent to the use of such data from such sources, to the extent required,
except for such failures to obtain written consent which (individually or in the aggregate) would not reasonably be expected to have a
Material Adverse Effect.


 


(xx)          
Except as disclosed in the Registration Statement and the Prospectus,
the Company has established and maintains disclosure controls and procedures over financial reporting (as defined in Rules 13a-15 and
15d-15 under the Exchange Act) and such controls and procedures are designed to ensure that information relating to the Company required
to be disclosed in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company's management,
including its principal executive and financial officer, or persons performing similar functions, as appropriate to allow timely decisions
regarding required disclosure. The Company has utilized such controls and procedures in preparing and evaluating the disclosures in the
Registration Statement and in the Prospectus.


 


(xxi)        
Except as disclosed in the Registration Statement and the Prospectus,
neither the board of directors nor the audit committee has been informed, nor is the Company aware, of: (i) any significant deficiencies
or material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the Company's ability to record, process, summarize and report financial information; or (ii) any fraud, whether or not material,
that involves management or other employees who have a significant role in the Company's internal control over financial reporting.


 





     


     


    




(xxii)     
The Company has not taken, directly or indirectly, any action which
constitutes or is designed to cause or result in, or which could reasonably be expected to constitute, cause or result in, the stabilization
or manipulation of the price of any security to facilitate the sale or resale of the Shares.


 


(xxiii)   
Neither the Company nor any of its Affiliates (within the meaning
of the Securities Act) has, prior to the date hereof, made any offer or sale of any securities which are required to be "integrated"
pursuant to the Securities Act or the Rules and Regulations with the offer and sale of the Shares pursuant to the Registration Statement.
Except as disclosed in the Registration Statement and the Prospectus, neither the Company nor any of its Affiliates has sold or issued
any securities during the six-month period preceding the date of the Prospectus, including but not limited to any sales pursuant to Rule
144A, Regulation D or Regulation S under the Securities Act, other than shares of Common Stock issued pursuant to equity incentive plans,
employee stock purchase plans, employee benefit plans, qualified stock option plans or employee compensation plans or pursuant to outstanding
options, convertible notes, convertible preferred stock, rights or warrants to purchase shares of Common Stock.


 


(xxiv)    
To the knowledge of the Company, the biographies of the Company's
officers and directors incorporated into the Registration Statement are true and correct in all material respects and the Company has
not become aware of any information which would cause the information disclosed in the questionnaires previously completed by the directors
and officers of the Company to become inaccurate and incorrect in any material respect.


 


(xxv)      
To the knowledge of the Company, no director or officer of the
Company is subject to any non-competition agreement or non-solicitation agreement with any employer or prior employer which could materially
affect his or her ability to be and act in his or her respective capacity of the Company.


 


(xxvi)    
The Company is not and, at all times up to and including the consummation
of the transactions contemplated by this Agreement, and after giving effect to application of the Net Proceeds (as defined below), will
not be, subject to registration as an "investment company" under the Investment Company Act of 1940, as amended, and is not
and will not be an entity "controlled" by an "investment company" within the meaning of such act.


 






     


     


    

 


(xxvii) 
No relationship, direct or indirect, exists between or among any
of the Company or, to the Company's knowledge, any Affiliate of the Company, on the one hand, and any director, officer, stockholder,
customer or supplier of the Company or, to the Company's knowledge, any Affiliate of the Company, on the other hand, which is required
by the Securities Act, the Exchange Act or the Rules and Regulations to be described in the Registration Statement or the Prospectus which
is not so described as required. There are no outstanding loans, advances (except normal advances for business expenses in the ordinary
course of business) or guarantees of indebtedness by the Company to or for the benefit of any of the officers or directors of the Company
or any of their respective family members, except as described in the Registration Statement and the Prospectus. The Company has not,
in violation of Sarbanes-Oxley, directly or indirectly extended or maintained credit, arranged for the extension of credit, or renewed
an extension of credit, in the form of a personal loan to or for any director or executive officer of the Company.


 


(xxviii)                       
Except as disclosed in the Registration Statement and the Prospectus,
the Company is in compliance with the rules and regulations promulgated by The NASDAQ Stock Market LLC or any other governmental or self-regulatory
entity or agency having jurisdiction over the Company, except for such failures to be in compliance which (individually or in the aggregate)
would not reasonably be expected to have a Material Adverse Effect. Without limiting the generality of the foregoing: (i) all members
of the Company's board of directors who are required to be "independent" (as that term is defined under the rules of The NASDAQ
Stock Market LLC), including, without limitation, all members of the audit committee of the Company's board of directors, meet the qualifications
of independence as set forth under applicable laws, rules and regulations and (ii) the audit committee of the Company's board of directors
has at least one member who is an "audit committee financial expert" (as that term is defined under applicable laws, rules and
regulations).


 


(xxix)    
The Company and each of its Subsidiaries owns or leases all such
properties (other than intellectual property, which is covered below) as are necessary to the conduct of its business as presently operated
and as described in the Registration Statement and the Prospectus. The Company and each of its Subsidiaries has good and marketable title
in fee simple to all real property and good and marketable title to all personal property owned by it, in each case free and clear of
all Liens except such as are described in the Registration Statement and the Prospectus or such as would not (individually or in the aggregate)
have a Material Adverse Effect. Any real property and buildings held under lease or sublease by the Company or its Subsidiaries are held
by it under valid, subsisting and, to the Company's knowledge, enforceable leases with such exceptions as are not material to, and do
not materially interfere with, the use made and proposed to be made of such property and buildings by the Company or its Subsidiaries.
Neither the Company nor its Subsidiaries has received any written notice of any claim adverse to its ownership of any real or material
personal property or of any claim against the continued possession of any real property, whether owned or held under lease or sublease
by the Company or its Subsidiaries, except for such claims that, if successfully asserted against the Company or its Subsidiaries, would
not (individually or in the aggregate) reasonably be expected to have a Material Adverse Effect.


 






     


     


    

 


(xxx)      
The Company (including all of its Subsidiaries): (i) owns, possesses
or has the right to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark
registrations, copyrights, licenses, formulae, customer lists and know-how and other intellectual property (including trade secrets and
other unpatented and/or unpatentable proprietary or confidential information, systems or procedures, "Intellectual Property")
necessary for the conduct of its businesses as being conducted and as described in the Registration Statement and the Prospectus, except
as disclosed in the Registration Statement or the Prospectus, and (ii) has no knowledge that the conduct of its business conflicts or
will conflict with the rights of others, and it has not received any written notice of any claim of conflict with, any right of others.
To the Company's knowledge, there is no infringement by third parties of any such Intellectual Property. There is no pending or, to the
Company's knowledge, threatened, action, suit, proceeding or claim by others challenging the Company's rights in or to any such Intellectual
Property, and the Company is unaware of any facts which would form a reasonable basis for any such claim; and there is no pending or,
to the Company's knowledge, threatened, action, suit, proceeding or claim by others that the Company infringes or otherwise violates any
patent, trademark, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any other fact which would
form a reasonable basis for any such claim. Except as set forth in the Registration Statement and the Prospectus, the Company has not
received any claim for royalties or other compensation from any person, including any employee of the Company who made inventive contributions
to Company's technology or products that are pending or unsettled, and except as set forth in the Registration Statement and the Prospectus
the Company does not and will not have any obligation to pay royalties or other compensation to any person on account of inventive contributions.


 






     


     


    

 


(xxxi)    
The agreements and documents described in the Registration Statement
and the Prospectus conform in all material respects to the descriptions thereof contained therein and there are no agreements or other
documents required by the applicable provisions of the Securities Act to be described in the Registration Statement or the Prospectus
or to be filed with the Commission as exhibits to the Registration Statement, that have not been so described or filed. Each agreement
or other instrument (however characterized or described) to which the Company (or its Subsidiaries) is a party or by which its property
or business is or may be bound or affected and (i) that is referred to in the Registration Statement or the Prospectus or attached as
an exhibit thereto, or (ii) is material to the Company's business, has been duly and validly executed by the Company, is in full force
and effect in all material respects and is enforceable against the Company in accordance with its terms, except (x) as such enforceability
may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors' rights generally, (y) as enforceability
of any indemnification or contribution provision may be limited under the foreign, federal and state securities laws, and (z) that the
remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the
discretion of the court before which any proceeding therefor may be brought, and none of such agreements or instruments has been assigned
by the Company (including any Subsidiaries), and neither the Company nor, to the Company's knowledge, any other party is in material breach
or default thereunder and, to the Company's knowledge, no event has occurred that, with the lapse of time or the giving of notice, or
both, would constitute a breach or default thereunder, in any such case, which would result in a Material Adverse Effect.


 


(xxxii) 
The disclosures in the Registration Statement and the Prospectus
concerning the effects of foreign, federal, state and local regulation on the Company's business as currently contemplated are correct
in all material respects.


 


(xxxiii)                       
The Company has accurately prepared and filed all federal, state,
foreign and other tax returns that are required to be filed by it through the date hereof, or has received timely extensions thereof,
except where the failure to so file would not (individually or in the aggregate) reasonably be expected to have a Material Adverse Effect,
and has paid or made provision for the payment of all material taxes, assessments, governmental or other similar charges, including without
limitation, all sales and use taxes and all taxes which the Company is obligated to withhold from amounts owing to employees, creditors
and third parties, with respect to the periods covered by such tax returns, whether or not such amounts are shown as due on any tax return
(except as currently being contested in good faith and for which reserves required by GAAP have been created in the financial statements
of the Company) and except for such taxes, assessments, governmental or other similar charges the nonpayment of which would not (individually
or in the aggregate) reasonably be expected to have a Material Adverse Effect. No deficiency assessment with respect to a proposed adjustment
of the Company's federal, state, local or foreign taxes is pending or, to the Company's knowledge, threatened. The accruals and reserves
on the books and records of the Company in respect of tax liabilities for any taxable period not finally determined are adequate to meet
any assessments and related liabilities for any such period and, since the date of the Company's most recent audited financial statements,
the Company has not incurred any material liability for taxes other than in the ordinary course of its business. There is no tax lien,
whether imposed by any federal, state, foreign or other taxing authority, outstanding against the assets, properties or business of the
Company.


 






     


     


    

 


(xxxiv)
No labor disturbance or dispute by or with the employees of the Company which,
individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect, currently exists or, to the Company's
knowledge, is threatened. The Company is in compliance in all material respects with the labor and employment laws and collective bargaining
agreements and extension orders applicable to its employees.


 


(xxxv)  
Except as would not be reasonably expected, individually or in
the aggregate, to have a Material Adverse Effect, the Company (and its Subsidiaries) is in compliance with all material Environmental
Laws (as hereinafter defined), and, to the Company's knowledge, no future material expenditures are or will be required in order to comply
therewith. The Company has not received any written notice or communication that relates to or alleges any actual or potential violation
or failure to comply with any Environmental Laws that would, individually or in the aggregate, be reasonably expected to have a Material
Adverse Effect. As used herein, the term "Environmental Laws" means all applicable laws and regulations, including
any licensing, permits or reporting requirements, and any action by a federal, state or local government entity, pertaining to the protection
of the environment, protection of public health, protection of worker health and safety, or the handling of hazardous materials, including
without limitation, the Clean Air Act, 42 U.S.C. § 7401, et seq., the Comprehensive Environmental Response, Compensation and Liability
Act of 1980, 42 U.S.C. § 9601, et seq., the Federal Water Pollution Control Act, 33 U.S.C. § 1321, et seq., the Hazardous Materials
Transportation Act, 49 U.S.C. § 1801, et seq., the Resource Conservation and Recovery Act, 42 U.S.C. § 690-1, et seq., and the
Toxic Substances Control Act, 15 U.S.C. § 2601, et seq.


 


(xxxvi)
As to each product or product candidate subject to the jurisdiction of the U.S.
Food and Drug Administration (FDA) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder ("FDCA")
and/or the jurisdiction of the non-U.S. counterparts thereof that is currently being tested by the Company (or any of its Subsidiaries)
(each such product, a "Product"), such Product is being tested by the Company in compliance with all applicable
requirements under FDCA and/or and similar laws, rules and regulations relating to registration, investigational use, premarket clearance,
licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing,
quotas, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse
Effect. Except as disclosed in the Registration Statement and the Prospectus, the Company currently has no products that have been approved
by the FDA or any non-U.S. counterparts thereof to be manufactured, packaged, labeled, distributed, sold and/or marketed. Except as disclosed
in the Registration Statement or the Prospectus, there is no pending, completed or, to the Company's knowledge, threatened, action (including
any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company
and the Company has not received any written notice, warning letter or other communication from the FDA or any other governmental entity
or any non-U.S. counterparts thereof, in either case which (i) contests the premarket clearance, licensure, registration or approval of,
the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any
Product, (ii) imposes a clinical hold on any clinical investigation by the Company, (iii) enters or proposes to enter into a consent decree
of permanent injunction with the Company, or (iv) otherwise alleges any violation of any laws, rules or regulations by the Company, and
which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company
have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA and
non-U.S. counterparts thereof. The Company has not been informed by the FDA or any non-U.S. counterparts thereof that such agency will
prohibit the marketing, sale, license or use of any Product nor has the FDA or a non-U.S. counterpart thereof provided any written notice
that could reasonably be expected to preclude the approval or the clearing for marketing of any Product.


 






     


     


    

 


(xxxvii)  The clinical, pre-clinical and other studies and tests ("Studies")
conducted by or on behalf of or sponsored by the Company (including its Subsidiaries) that are described or referred to in the Registration
Statement and the Prospectus were and, if still pending, are, being conducted in accordance with all applicable statutes, laws, rules
and regulations (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental
or regulatory authority performing functions similar to those performed by the FDA), as well as the protocols, procedures and controls
designed and approved for such Studies and with standard medical and scientific research procedures, except where the failure to be so
conducted would not have a Material Adverse Effect. The descriptions of the results of such Studies that are described or referred to
in the Registration Statement and the Prospectus are accurate and complete in all material respects and fairly present the data derived
from such Studies. Except as disclosed in the Registration Statement and the Prospectus, the Company has not received any written notices
or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions
similar to those performed by the FDA requiring the termination or suspension of such Studies, other than ordinary course communications
with respect to modifications in connection with the design and implementation of such Studies.


 


(xxxviii) Except as would not result in a Material Adverse Effect, the Company
(including its Subsidiaries) has not failed to file with the applicable regulatory authorities (including the FDA or any foreign, federal,
state or local governmental or regulatory authority performing functions similar to those performed by the FDA and having jurisdiction
over the Company) any filing, declaration, listing, registration, report or submission that is required to be so filed for the Company's
business operation as currently conducted. All such filings were in material compliance with applicable laws when filed and no material
deficiencies have been asserted in writing by any applicable regulatory authority (including, without limitation, the FDA or any foreign,
federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA) with respect
to any such filings, declarations, listings, registrations, reports or submissions.


 


(xxxix)
The Registration Statement and the Prospectus identify each employment, severance
or other similar agreement, arrangement or policy and each material arrangement providing for insurance coverage, benefits, bonuses, stock
options or other forms of incentive compensation, or post-retirement insurance, compensation or benefits which: (i) is entered into, maintained
or contributed to, as the case may be, by the Company and (ii) covers any officer or director or former officer or former director of
the Company, in each case to the extent required by the Rules and Regulations. These contracts, plans and arrangements are referred to
collectively in this Agreement as the "Benefit Arrangements." Each Benefit Arrangement has been maintained in
material compliance with its terms and with requirements prescribed by any and all statutes, orders, rules and regulations that are applicable
to that Benefit Arrangement in each case except where the failure to comply is not reasonably likely to have a Material Adverse Effect.


 






     


     


    

 


(xl)  Except as set forth in the Registration Statement or the Prospectus,
the Company is not a party to or subject to any employment contract or arrangement providing for annual future compensation, or the opportunity
to earn annual future compensation (whether through fixed salary, bonus, commission, options or otherwise) of more than $120,000 to any
executive officer or director.


 


(xli) The conditions for use of Form S-3 to register the Offering under
the Securities Act, as set forth in the General Instructions to such Form, have been satisfied.


 


(xlii) Except as disclosed in the Registration Statement and the Prospectus,
neither the execution of this Agreement nor the consummation of the Offering, constitutes a triggering event under any Benefit Arrangement
or any other employment contract, whether or not legally enforceable, which (either alone or upon the occurrence of any additional or
subsequent event) will or may result in any payment (of severance pay or otherwise), acceleration, increase in vesting or increase in
benefits to any current or former participant, employee or director of the Company other than an event that is not material to the financial
condition or business of the Company.


 


(xliii)  Neither the Company nor, to the Company's knowledge, any of its
employees or agents, has at any time during the last three (3) years: (i) made any unlawful contribution to any candidate for foreign
office, or failed to disclose fully any contribution in violation of law, or (ii) made any payment to any federal or state governmental
officer or official or other person charged with similar public or quasi-public duties in the United States, other than payments that
are not prohibited by the laws of the United States or any jurisdiction thereof.


 


(xliv)  The Company has not offered, or caused the Agent to offer, any
Shares to any person or entity with the intention of unlawfully influencing: (i) a supplier of the Company to alter the supplier's level
or type of business with the Company or (ii) a journalist or publication to write or publish favorable information about the Company.


 


(xlv)  The operations of the Company are and have been conducted at all
times in compliance in all material respects with applicable financial record keeping and reporting requirements and money laundering
statutes of the United States and, to the Company's knowledge, all other applicable jurisdictions to which the Company is subject, the
rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any
applicable governmental agency (collectively, the "Money Laundering Laws"), and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering
Laws is pending or, to the Company's knowledge, threatened.


 






     


     


    

 


(xlvi)     
Neither the Company nor, to the Company's knowledge, any director,
officer, agent, employee or Affiliate of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department ("OFAC"); and the Company will not directly or indirectly use the
proceeds of the Offering, or lend, contribute or otherwise make available such proceeds to any joint venture partner or other person or
entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.


 


(xlvii)   
(i)(x) There has been no security breach or other compromise of or relating to any of the Company’s or any Subsidiary’s
information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees,
suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, “IT Systems
and Data”) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition
that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and
the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of
any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy
and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the
Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information
and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries
have implemented backup and disaster recovery technology consistent with industry standards and practices.


 


(xlviii) 
None of the Company, its directors or officers or, to the Company's
knowledge, any agent, employee, affiliate or other person acting on behalf of the Company has engaged in any activities sanctionable under
the Comprehensive Iran Sanctions, Accountability, and Divestment Act of 2010, the Iran Sanctions Act of 1996, the National Defense Authorization
Act for Fiscal Year 2012, the Iran Threat Reduction and Syria Human Rights Act of 2012 or any Executive Order relating to any of the foregoing
(collectively, and as each may be amended from time to time, the "Iran Sanctions"); and the Company will not directly
or indirectly use the proceeds of the Offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint
venture partner or other person or entity, for the purpose of engaging in any activities sanctionable under the Iran Sanctions.


 






     


     


    




 


(xlix)     
Except as described in the Registration Statement and the Prospectus,
there are no claims, payments, arrangements, agreements or understandings relating to the payment of a finder's, consulting or origination
fee by the Company or any officer, director or stockholder of the Company (each, an "Insider") with respect to
the sale of the Shares hereunder or any other arrangements, agreements or understandings of the Company or, to the Company's knowledge,
any of its stockholders that may affect the Agent's compensation, as determined by FINRA. Except as described in the Registration Statement
and the Prospectus, the Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as
a finder's fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company
persons who raised or provided capital to the Company; (ii) to any FINRA member; or (iii) to any person or entity that has any direct
or indirect affiliation or association with any FINRA member, within the 180 days prior to the Effective Date. None of the Net Proceeds
will be paid by the Company to any participating FINRA member or its affiliates, except as specifically authorized herein. No officer,
director or, to the Company's knowledge, any beneficial owner of 5% or more of the Company's securities (whether debt or equity, registered
or unregistered, regardless of the time acquired or the source from which derived) (any such individual or entity, a "Company
Affiliate") has any direct or indirect affiliation or association with any FINRA member (as determined in accordance with
the rules and regulations of FINRA); no Company Affiliate is an owner of stock or other securities of any member of FINRA (other than
securities purchased on the open market); no Company Affiliate has made a subordinated loan to any member of FINRA; and no Net Proceeds
from the sale of the Shares will be paid to any FINRA member, or any persons associated with or affiliated with any member of FINRA. Except
as disclosed in the Registration Statement and the Prospectus, the Company has not issued any warrants or other securities or granted
any options, directly or indirectly, to anyone who is a potential underwriter in the Offering or a related person (as defined by FINRA
rules) of such an underwriter within the 180-day period prior to the initial filing date of the Registration Statement; no person to whom
securities of the Company have been privately issued within the 180-day period prior to the initial filing date of the Registration Statement
has any relationship or affiliation or association with any member of FINRA; and no FINRA member participating in the offering has a conflict
of interest with the Company. For this purpose, a "conflict of interest" has the meaning ascribed to such term in FINRA Rule
5121(f)(5).


 






     


     


    

 


(l)                
The Company has not distributed and will not distribute any prospectus
or other offering material in connection with the Offering other than the Registration Statement and the Prospectus or other materials
permitted by the Securities Act to be distributed by the Company; provided, however, that the Company has not made and will not make any
offer relating to the Shares that would constitute a "free writing prospectus" as defined in Rule 405 under the Securities Act,
except any Permitted Free Writing Prospectus.


 


(b) Any certificate signed
by any officer of the Company and delivered to the Agent or the Agent's counsel shall be deemed a representation and warranty by the Company
to Agent as to the matters covered thereby.


 


(c) At the effective date
of the Registration Statement, each Bringdown Date (as hereinafter defined) and each Time of Sale, the Company shall be deemed to have
affirmed each representation and warranty contained in or made pursuant to this Agreement as of such date as though made at and as of
such date (except that such representations and warranties shall be deemed to relate to the Registration Statement and the Prospectus
as amended and supplemented relating to such Shares on such date).


 


(d) As used in this Agreement,
references to matters being "material" with respect to the Company shall mean a material event, change, condition,
status or effect related to the condition (financial or otherwise), properties, assets (including intangible assets), liabilities, business,
prospects, operations or results of operations of the Company, either individually or taken as a whole, as the context requires.


 


(e) As used in this Agreement,
the term "to the Company's knowledge" (or similar language) shall mean the knowledge of the executive officers
and directors of the Company who are named in the Prospectus, with the assumption that such executive officers and directors shall have
made reasonable and diligent inquiry of the matters presented (with reference to what is customary and prudent for the applicable individuals
in connection with the discharge by the applicable individuals of their duties as executive officers or directors of the Company).


 


2.
Purchase, Sale and Delivery of Shares.


 


(a) At the Market Sales.
On the basis of the representations, warranties and agreements herein the Company agrees that, from time to time after the effective date
of the Registration Statement on the terms and subject to the conditions set forth herein, it may issue and sell through the Agent, acting
as sales agent, Shares having an aggregate offering price of up to $2,700,000 (the "Offering Size"); provided,
however, that in no event shall the Company issue or sell through the Agent such number of Shares that (a) exceeds the number or dollar
amount of shares of Common Stock registered on the Registration Statement pursuant to which the Offering is being made, (b) exceeds the
number of authorized but unissued shares of Common Stock under the Company’s Restated Certificate of Incorporation, as amended or
(c) would cause the Company or the Offering to not satisfy the eligibility and transaction requirements for use of Form S-3 (including,
if then applicable, General Instruction I.B.6 of Form S-3) (the lesser of (a), (b) and (c), the "Maximum Amount").
Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set forth in
this Section 2(a) on the number and aggregate sales price of Shares issued and sold under this Agreement shall be the sole responsibility
of the Company and the Agent shall have no obligation in connection with such compliance. Notwithstanding the foregoing, the Company agrees
that it will provide the Agent with written notice no less than one (1) business day prior to the date on which it makes the initial sale
of Shares under this Agreement.


 






     


     


    

 


(i)    For purposes of selling the Shares through the Agent, the Company hereby appoints the Agent as exclusive agent of the Company
(including in the event the Company increases the Offering Size) for the purpose of soliciting purchases of the Shares from the Company
pursuant to this Agreement and the Agent agrees to use its commercially reasonable efforts to sell the Shares on the terms and subject
to the conditions stated herein.


 


(ii)   Each time the Company wishes to issue and sell the Shares hereunder (each, a "Transaction"), it
will notify the Agent by telephone (confirmed promptly by e-mail to the appropriate individual listed on Schedule D hereto, using
a form substantially similar to that set forth on Schedule C hereto) (a "Transaction Notice") as to the
maximum number of Shares to be sold by the Agent on such day and in any event not in excess of the amount available for issuance under
the Prospectus and the currently effective Registration Statement, the time period during which sales are requested to be made, any limitation
on the number of shares that may be sold in any one Trading Day (as defined below), and any minimum price below which sales may not be
made. The Transaction Notice shall originate from any of the individuals from the Company set forth on Schedule B (with a copy
to each of the other individuals from the Company listed on such Schedule), and shall be addressed to each of the individuals from the
Agent set forth on Schedule D, as such Schedule D may be amended from time to time. Subject to the terms and conditions
hereof and unless the sale of the Shares described therein has been declined, suspended, or otherwise terminated in accordance with the
terms of this Agreement, the Agent shall promptly acknowledge the Transaction Notice by e-mail (or by some other method mutually agreed
to in writing by the parties) and shall use its commercially reasonable efforts to sell all of the Shares so designated by the Company
in the Transaction Notice and in accordance with the terms set forth herein; provided, however, that any obligation of the Agent to use
such commercially reasonable efforts shall be subject to the continuing accuracy of the representations and warranties of the Company
herein, to the performance by the Company of its obligations hereunder and to the continuing satisfaction of the additional conditions
specified in Section 4 of this Agreement. The gross sales price of the Shares sold under this Section 2(a) shall be equal
to the market price for the Common Stock sold by the Agent under this Section 2(a) on the NASDAQ Capital Market at the time of
such sale. For the purposes hereof, "Trading Day" means any day on which shares of Common Stock are purchased
and sold on the principal market on which the Common Stock is listed or quoted.


 






     


     


    

 


(iii)  The Company or the Agent may, upon notice to the other party hereto by telephone (confirmed promptly by e-mail to the respective
individuals of the other party set forth on Schedule D hereto, which confirmation shall be promptly acknowledged by the other party),
suspend the Offering for any reason and at any time, whereupon the Agent shall so suspend the offering of Shares until further notice
is provided by the other party to the contrary; provided, however, that such suspension or termination shall not affect
or impair the parties' respective obligations with respect to the Shares sold hereunder prior to the receipt by the Agent of such notice.
Each of the parties agrees that no such notice under this Section 2(a)(iii) shall be effective against the other unless it is made
to one of the individuals named on Schedule D hereto, as such Schedule may be amended from time to time. Notwithstanding the foregoing,
if the Agent suspends the Offering for any three (3) consecutive business days or on more than three (3) separate occasions (in each instance
other than as a result of the Company’s breach of its obligations hereunder), the Company, in its sole discretion, may elect to
terminate this Agreement.


 


(iv)  The Company acknowledges and agrees that (A) there can be no assurance that the Agent will be successful in selling the
Shares, (B) the Agent will incur no liability or obligation to the Company or any other person or entity if it does not sell Shares for
any reason other than a failure by the Agent to use its commercially reasonable efforts consistent with its normal trading and sales practices
and applicable law and regulations to sell such Shares as required under this Agreement, and (C) the Agent shall be under no obligation
to purchase shares on a principal basis pursuant to this Agreement.


 


(v)   The Agent may sell Shares by any method permitted by law to be an “at-the-market offering” as defined in Rule
415 of the Securities Act including without limitation sales made directly on the NASDAQ Capital Market, on any other existing trading
market for the Common Stock or to or through a market maker. With the prior written consent of the Company, which may be provided in a
Transaction Notice, the Agent may also sell Shares in privately negotiated transactions.


 






     


     


    

 


(vi)    The compensation to the Agent for sales of the Shares, as an agent of the Company, shall be 3.00% (the “Transaction
Fee”) of the gross sales price of all of Shares sold pursuant to this Section 2(a). The remaining proceeds, after
further deduction for any transaction or other fees imposed by any governmental or self-regulatory organization in respect of such sales,
shall constitute the net proceeds to the Company for such Shares (the "Net Proceeds"). The Agent shall notify
the Company as promptly as practicable if any deduction referenced in the preceding sentence will be required.


 


(vii)   In addition, Maxim shall be entitled to a Transaction Fee with respect to any public or private offering or other financing
or capital-raising transaction of any kind (a “Tail Financing”) to the extent such financing or capital is provided
to the Company by investors introduced by Maxim, directly or indirectly, to the Company during the term of this Agreement if such Tail
Financing is consummated at any time within the twelve (12) month period following the expiration or termination of this Agreement. For
the avoidance of doubt, this provision is not intended to and does not extend the right of first refusal period set forth in either Section
14 of that certain Engagement Agreement, dated June 10, 2021 by and between the Company and Maxim or Section 4.20 of that certain Underwriting
Agreement, dated December 21, 2021, by and between the Company and Maxim.


 


(viii)  The Agent shall provide written confirmation to the Company following the close of trading on the NASDAQ Capital Market
each day in which the Shares are sold under this Section 2(a) setting forth the number of the Shares sold on such day, the aggregate
gross sale proceeds, the Net Proceeds to the Company, and the compensation payable by the Company to the Agent with respect to such sales.


 


(ix)     All Shares sold pursuant to this Section 2(a) will be delivered by the Company to Agent for the accounts of the Agent
on the second full business day following the date on which such Shares are sold, or at such other time and date as Agent and the Company
determine pursuant to Rule 15c6-1(a) under the Exchange Act, each such time and date of delivery being herein referred to as a "Settlement
Date." On each Settlement Date, the Shares sold through the Agent for settlement on such date shall be issued and delivered
by the Company to the Agent against payment of the Net Proceeds from the sale of such Shares. Settlement for all such Shares shall be
effected by free delivery of the Shares by the Company or its transfer agent (i) to the Agent or its designee's account (provided the
Agent shall have given the Company written notice of such designee prior to the Settlement Date) at The Depository Trust Company ("DTC")
or (ii) by such other means of delivery as may be mutually agreed upon by the parties hereto, which in all cases shall be freely tradable,
transferable, registered shares in good deliverable form, in return for payment in same day funds delivered to an account designated by
the Company. If the Company or its transfer agent (if applicable) shall default on its obligation to deliver the Shares on any Settlement
Date, the Company shall (A) indemnify and hold the Agent harmless against any loss, claim or damage arising from or as a result of such
default by the Company and (B) pay the Agent any commission to which it would otherwise be entitled absent such default. If the Agent
breaches this Agreement by failing to deliver the Net Proceeds on any Settlement Date for the shares delivered by the Company, the Agent
will pay the Company interest based on the effective prime rate until such proceeds, together with such interest, have been fully paid.


 






     


     


    

 


(x)   Under no circumstances shall the Company cause or request the offer or sale of any Shares if, after giving effect to the
sale of such Shares, the aggregate gross sales proceeds sold pursuant to this Agreement would exceed the lesser of (A) together with all
sales of Shares under this Agreement, the Maximum Amount, (B) the amount available for offer and sale under the currently effective Registration
Statement and (C) the amount authorized from time to time to be issued and sold under this Agreement by the Company's board of directors,
a duly authorized committee thereof or a duly authorized executive committee, and notified to the Agent in writing. Under no circumstances
shall the Company cause or request the offer or sale of any Shares at a price lower than the minimum price authorized from time to time
by the Company's board of directors, duly authorized committee thereof or a duly authorized executive committee, and notified to the Agent
in writing. Further, under no circumstances shall the aggregate offering amount of Shares sold pursuant to this Agreement, including any
separate underwriting or similar agreement covering principal transactions, exceed the Maximum Amount.


 


(xi)  The Company agrees that any offer to sell, any solicitation of an offer to buy, or any sales of Shares shall only be effected
by or through the Agent; provided, however, that the foregoing limitation shall not apply to the exercise of any outstanding option or
warrant or conversion of any outstanding convertible preferred stock or convertible notes described in the Registration Statement and
the Prospectus.


 


(b)  Nothing
herein contained shall constitute the Agent an unincorporated association or partner with the Company. Under no circumstances shall any
Shares be sold pursuant to this Agreement after the date which is three years after the Registration Statement was first declared effective
by the Commission.


 






     


     


    

 


(c)  Notwithstanding
any other provisions of this Agreement, the Company agrees that no sale of Shares shall take place, and the Company shall not request
the sale of any Shares, and the Agent shall not be obligated to sell, during any period in which the Company is, or could be deemed to
be, in possession of material non-public information.


 


(d)  Unless
the exceptive provisions set forth in Rule 101(c)(1) of Regulation M under the Exchange Act are satisfied with respect to the
Shares, the Company shall give the Agent at least one Business Day’s prior notice of its intent to sell any Shares in order to allow
the Agent time to comply with Regulation M.


 


3.
Covenants. The Company covenants and agrees with the Agent as follows:


 


(a)  After
the date hereof and through any Prospectus Delivery Period, prior to amending or supplementing the Registration Statement (including any
Rule 462(b) Registration Statement), Base Prospectus, the Prospectus or any Permitted Free Writing Prospectus, the Company shall furnish
to the Agent for review a copy of each such proposed amendment or supplement, allow the Agent a reasonable amount of time to review and
comment on such proposed amendment or supplement, and the Company shall not file any such proposed amendment or supplement to which the
Agent or counsel to the Agent reasonably object; provided that the foregoing shall not apply with regards to the filing by the Company
of any Form 10-K, 10-Q, 8-K, proxy statement or other Incorporated Document. Subject to this Section 3(a), immediately following
execution of this Agreement, if not previously prepared, the Company will prepare a prospectus supplement describing the selling terms
of the Shares hereunder, the plan of distribution thereof and such other information as may be required by the Securities Act or the Rules
and Regulations or as the Agent and the Company may deem appropriate, and if requested by the Agent, a Permitted Free Writing Prospectus
containing the selling terms of the Shares hereunder and such other information as the Company and the Agent may deem appropriate, and
will file or transmit for filing with the Commission, in accordance with Rule 424(b) or Rule 433, as the case may be, copies of the Prospectus
as supplemented and each such Permitted Free Writing Prospectus.


 


(b)  After
the date of this Agreement, the Company shall promptly advise the Agent in writing (i) of the receipt of any comments of, or requests
for additional or supplemental information from, the Commission (including, for the avoidance of doubt, as it relates to the effectiveness
of the Registration Statement) or for any amendments or supplements to the Registration Statement, the Base Prospectus, the Prospectus
or any Permitted Free Writing Prospectus (excluding any Incorporated Documents), (ii) of the time and date of any filing of any post-effective
amendment to the Registration Statement or any amendment or supplement to any Base Prospectus, the Prospectus or any Permitted Free Writing
Prospectus (excluding any Incorporated Documents), (iii) of the time and date that any post-effective amendment to the Registration Statement
becomes effective, (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement
or any post-effective amendment thereto or of any order preventing or suspending its use or the use of any Base Prospectus, the Prospectus
or any Permitted Free Writing Prospectus, or (v) of any proceedings to remove, suspend or terminate from listing or quotation the Common
Stock from any securities exchange upon which it is listed for trading or included or designated for quotation, or of the threatening
or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time, the Company
may terminate this Agreement. Additionally, the Company agrees that it shall comply with the provisions of Rules 424(b), 430B and 430C,
as applicable, under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule
424(b), Rule 433 or Rule 462 were received in a timely manner by the Commission (without reliance on Rule 424(b)(8) or Rule 164(b)).


 






     


     


    

 


(c)  From
the date hereof through the later of (A) the termination of this Agreement and (B) the end of any applicable Prospectus Delivery Period,
the Company will comply in all material respects with all requirements imposed upon it by the Securities Act, as now and hereafter amended,
and by the Rules and Regulations, as from time to time in force, and by the Exchange Act so far as necessary to permit the continuance
of sales of or dealings in the Shares as contemplated by the provisions hereof, the Base Prospectus, the Prospectus and any Permitted
Free Writing Prospectus. If during any applicable Prospectus Delivery Period any event occurs as a result of which the Base Prospectus,
the Prospectus, or any Permitted Free Writing Prospectus would include an untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during any applicable
Prospectus Delivery Period it is necessary or appropriate in the opinion of the Company or its counsel or in the reasonable opinion of
the Agent or counsel to the Agent to amend the Registration Statement or supplement the Base Prospectus, the Prospectus or any Permitted
Free Writing Prospectus, to comply with the Securities Act or to file under the Exchange Act any document which would be deemed to be
incorporated by reference in the Prospectus in order to comply with the Securities Act or the Exchange Act, the Company will promptly
notify Agent (or the Agent will notify the Company, as applicable), and the Agent shall suspend the offering and sale of any such Shares,
and the Company will amend the Registration Statement or supplement the Base Prospectus, the Prospectus or any Permitted Free Writing
Prospectus or file such document (at the expense of the Company) so as to correct such statement or omission or effect such compliance
within the time period prescribed by the Securities Act or the Exchange Act.


 


(i)
   In case the Agent is required to deliver (whether physically
or through compliance with Rule 172 under the Securities Act or any similar rule), in connection with the sale of the Shares, a Prospectus
after the nine-month period referred to in Section 10(a)(3) of the Securities Act, or after the time a post-effective amendment to the
Registration Statement is required pursuant to Item 512(a) of Regulation S-K under the Securities Act, the Company will prepare, at its
expense, promptly upon request such amendment or amendments to the Registration Statement and the Prospectus as may be necessary to permit
compliance with the requirements of Section 10(a)(3) of the Securities Act or Item 512(a) of Regulation S-K under the Securities Act,
as the case may be. The Company shall cause each amendment or supplement to any Base Prospectus or the Prospectus to be filed with the
Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act or, in the case of any document which
would be deemed to be incorporated by reference therein, to be filed with the Commission as required pursuant to the Exchange Act, within
the time period prescribed. The Company shall promptly notify the Agent if any Material Contract is terminated or if the other party thereto
gives written notice of its intent to terminate any such Material Contract.


 


(ii)
 If at any time following issuance of a Permitted Free Writing
Prospectus there occurs an event or development as a result of which such Permitted Free Writing Prospectus would conflict with the information
contained in the Registration Statement, the Base Prospectus or the Prospectus, or would include an untrue statement of a material fact
or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
prevailing at that subsequent time, not misleading, the Company promptly will notify the Agent and will promptly amend or supplement,
at its own expense, such Permitted Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.


 


(d)  The
Company shall use commercially reasonable efforts to take or cause to be taken all necessary action to qualify the Shares for sale under
the securities laws of such jurisdictions as Agent reasonably designates and to continue such qualifications in effect so long as required
for the distribution of the Shares, except that the Company shall not be required in connection therewith to qualify as a foreign corporation
or to execute a general consent to service of process in any state. The Company shall promptly advise the Agent of the receipt by the
Company of any notification with respect to the suspension of the qualification of the Shares for offer or sale in any jurisdiction or
the initiation or threatening of any proceeding for such purpose.


 






     


     


    

 


(e)  The
Company will furnish to the Agent and counsel for the Agent, to the extent requested, copies of the Registration Statement, the Base Prospectus,
the Prospectus, any Permitted Free Writing Prospectus, and all amendments and supplements to such documents, in each case as soon as available
and in such quantities as the Agent may from time to time reasonably request.


 


(f)   The
Company will make generally available to its security holders as soon as practicable an earnings statement (which need not be audited)
covering a 12-month period that shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 of the Rules and Regulations.
If the Company makes any public announcement or release disclosing its results of operations or financial condition for a completed quarterly
or annual fiscal period (each, an "Earnings Release") and the Company has not yet filed an Annual Report on Form
10-K or a Quarterly Report on Form 10-Q or a Form 8-K with respect to such information, as applicable, then, prior to any sale of Shares,
the Company shall be obligated to (x) file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b),
which prospectus supplement shall include the applicable financial information or (y) file a Report on Form 8-K, which Form 8-K shall
include the applicable financial information.


 


(g)  The
Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay or cause to
be paid (i) all expenses (including stock or transfer taxes and stamp or similar duties allocated to the respective transferees) incurred
in connection with the registration, issue, sale and delivery of the Shares, (ii) all reasonable expenses and fees (including, without
limitation, fees and expenses of the Company's accountants and counsel) in connection with the preparation, printing, filing, delivery,
and shipping of the Registration Statement (including the financial statements therein and all amendments, schedules, and exhibits thereto),
the Base Prospectus, each Prospectus, any Permitted Free Writing Prospectus, and any amendment thereof or supplement thereto, and the
producing, word-processing, printing, delivery, and shipping of this Agreement and other closing documents, including blue sky memoranda
(covering the states and other applicable jurisdictions) and including the cost to furnish copies of each thereof to the Agent, (iii)
all filing fees, (iv) listing fees, if any, and (v) all other costs and expenses of the Company incident to the performance of its obligations
hereunder that are not otherwise specifically provided for herein (including the costs and expenses related to any investor presentations
or “roadshow” undertaken in connection with marketing of the Shares as agreed to by the Company and expenses and disbursements
relating to background checks of the Company’s officers and directors). The Company shall reimburse the Agent upon request for its
actual, reasonable and documented costs and out-of-pocket expenses incurred in connection with this Agreement, whether or not the transactions
contemplated hereunder are consummated or this Agreement is terminated, including the actual, reasonable and documented fees and out-of-pocket
expenses of its legal counsel, up to $35,000. In addition, the Company shall pay the Agent $2,500 for its legal fees for each Bringdown
Date.


 






     


     


    

 


(h)  The
Company will apply the net proceeds from the sale of the Shares in the manner set forth under the caption "Use of Proceeds"
in the Base Prospectus, the Prospectus, and any Permitted Free Writing Prospectus.


 


(i)   The
Company will not, without (1) giving the Agent at least five business days' prior written notice specifying the nature of the proposed
sale and the date of such proposed sale, and (2) the Agent suspending activity under this Agreement for such period of time as requested
by the Company or as reasonably deemed appropriate by the Agent in light of the proposed sale, offer for sale, sell, contract to sell,
pledge, grant any option for the sale of, enter into any transaction which is designed to, or might reasonably be expected to, result
in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the Company
or any Subsidiary, or otherwise issue or dispose of, directly or indirectly (or publicly disclose the intention to make any such offer,
sale, pledge, grant, issuance or other disposition), of any Common Stock or any securities convertible into or exchangeable for, or any
options or rights to purchase or acquire, Common Stock, or permit the registration under the Securities Act of any Common Stock, such
securities, options or rights, except for (i) the registration of the Shares and the sales through the Agent pursuant to this Agreement,
(ii) the issuance of securities issuable upon exercise or conversion of any options, convertible preferred stock, convertible notes and
warrants that are outstanding as of the date of this Agreement and described in the Registration Statement and the Prospectus, and (iii)
the issuance of securities pursuant to any employee stock incentive plan, stock ownership plan or employee stock purchase plan of the
Company in effect at the time of this Agreement or any compensatory inducement grants made by the Company and approved by the Board consistent
with past practice.


 


(j)   The
Company shall not, at any time at or after the execution of this Agreement, offer or sell any of the Shares by means of any "prospectus"
(within the meaning of the Securities Act), or use any "prospectus" (within the meaning of the Securities Act) in connection
with the offer or sale of the Shares, in each case other than the Prospectus or any Permitted Free Writing Prospectus.


 


(k)  The Company has not taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to cause
or result in, or which has constituted, (i) the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of the Shares or (ii) a violation of Regulation M. The Company shall notify the Agent of any violation of Regulation
M by the Company or any of its officers or directors promptly after the Company has received notice or obtained knowledge of any such
violation.


 






     


     


    

 


(l)   The
Company will not incur any liability for any finder's or broker's fee or agent's commission in connection with the execution and delivery
of this Agreement or the consummation of the transactions contemplated hereby or thereby, except as contemplated herein.


 


(m)  During any applicable
Prospectus Delivery Period, the Company will file on a timely basis with the Commission such periodic and current reports as required
by the Rules and Regulations.


 


(n)  Except
as disclosed in the Registration Statement and the Prospectus, the Company has maintained, and will maintain, such controls and procedures,
including without limitation those required by Sections 302 and 906 of Sarbanes-Oxley and the applicable regulations thereunder, that
are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange
Act is recorded, processed, summarized and reported within the time periods specified in the Commission's rules and forms, including without
limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it
files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its principal executive
officer and its principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding
required disclosure, to ensure that material information relating to Company is made known to them by others within those entities.


 


(o)  Intentionally
omitted.


 


(p)  Each
of the Company and Agent hereby represent and agree that, neither the Company nor the Agent has made and will make any offer relating
to the Shares that would constitute an "issuer free writing prospectus," as defined in Rule 433 under the Securities Act, or
that would otherwise constitute a "free writing prospectus," as defined in Rule 405 under the Securities Act, required to be
filed with the Commission other than a Permitted Free Writing Prospectus. The Company represents that it has treated or agrees that it
will treat each Permitted Free Writing Prospectus as an "issuer free writing prospectus," as defined in Rule 433, and has complied
and will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely Commission filing
where required, legending and record keeping.


 






     


     


    

 


(q)  (1)
On or prior to the delivery of the first Transaction Notice issued hereunder, the Company shall cause Quick Law Group, P.C., counsel for
the Company, to furnish to the Agent its written opinion and negative assurance letter, in form and substance reasonably acceptable to
the Agent.


 


(2) On each date that the Company
(i) amends or supplements after the effective date of the Registration Statement the Registration Statement or the Prospectus (other than
by means of incorporation by reference); (ii) files an annual report on Form 10-K under the Exchange Act; (iii) files its quarterly reports
on Form 10-Q under the Exchange Act; (iv) files a report under Item 4.02 of Form 8-K under the Exchange Act containing amended financial
information; or (v) otherwise after each reasonable request by Agent (each of such date referred to herein as a "Bringdown
Date"), the Company shall cause Quick Law Group, P.C, counsel for the Company, to furnish to the Agent its negative assurance
letter, in form and substance reasonably acceptable to the Agent, dated as of a date within ten (10) days after the applicable Bringdown
Date, addressed to the Agent and modified as necessary to relate to the Registration Statement and the Prospectus as amended and supplemented
to the time of delivery of such opinions. With respect to this Section 3(q)(2), in lieu of delivering such opinions or letters
for Bringdown Dates subsequent to the date of effectiveness of the Registration Statement, such counsel may furnish agent with a letter
(a "Reliance Letter") to the effect that Agent may rely upon a prior opinion or letter delivered under Section
3(q)(1) or this Section 3(q)(2) to the same extent as if it were dated the date of such letter (except that statements in such
prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented as of the date of
Reliance Letter). Provided, however, the requirement to provide opinions and letters under this Section 3(q)(2) is hereby waived
for any Bringdown Date occurring at a time at which no Transaction Notice is pending, which waiver shall continue until the earlier to
occur of the date the Company delivers a Transaction Notice hereunder and the next occurring Bringdown Date. Notwithstanding the foregoing,
if the Company subsequently decides to sell Shares following a Bringdown Date when the Company relied on such waiver and did not provide
Agent with opinions and letters under this Section 3(q)(2), then before the Company delivers the Transaction Notice or Agent sells
any Shares, the Company shall cause Quick Law Group, P.C to furnish to the Agent a written opinion and negative assurance letter, dated
the date of the Transaction Notice.


 


(r)   On
or prior to the delivery of the first Transaction Notice issued hereunder and within ten (10) days after each Bringdown Date, the Company
shall cause the Auditor, or other independent accountants satisfactory to the Agent, to deliver to the Agent (x) a customary comfort letter
(the initial letter, the "Initial Comfort Letter," and each subsequent letter, a "Bringdown
Comfort Letter") addressed to Agent, in form and substance satisfactory to Agent, confirming that they are independent public
accountants within the meaning of the Securities Act and are in compliance with the applicable requirements relating to the qualifications
of accountants under Rule 2-01 of Regulation S-X of the Commission, and stating the conclusions and findings of said firm with respect
to the financial information and other matters and (y) a letter updating the Initial Comfort Letter with any information that would have
been included in the Initial Comfort Letter had it been given on such date and as modified as necessary to relate to the date of such
letter. Provided, however, the requirement to provide a Bringdown Comfort Letter under this Section 3(r) is hereby waived for any
Bringdown Date occurring at a time at which no Transaction Notice is pending, which waiver shall continue until the earlier to occur of
the date the Company delivers a Transaction Notice hereunder and the next occurring Bringdown Date. Notwithstanding the foregoing, if
the Company subsequently decides to sell Shares following a Bringdown Date when the Company relied on such waiver and did not provide
Agent with a Bringdown Comfort Letter under this Section 3(r), then before the Company delivers the Transaction Notice or Agent
sells any Shares, the Company shall cause the Auditor, or other independent accountants satisfactory to the Agent, to deliver to the Agent
a Bringdown Comfort Letter dated the date of the Transaction Notice.


 






     


     


    

 


(s)  On
or prior to the delivery of the first Transaction Notice issued hereunder and each Bringdown Date, the Company shall furnish to the Agent
an officer's certificate, dated as of a date within ten (10) days after the applicable Bringdown Date and addressed to Agent, signed by
the chief executive officer and by the chief financial officer of the Company, to the effect that:


 


(i)    The representations and warranties of the Company in this Agreement are true and correct in all material respects as if
made at and as of the date of the certificate, and the Company has complied in all material respects with all the agreements and satisfied
all the conditions on its part to be performed or satisfied at or prior to the date of the certificate;


 


(ii)   No stop order or other order suspending the effectiveness of the Registration Statement or any part thereof or any amendment
thereof or the qualification of the Shares for offering or sale or notice that would prevent use of the Registration Statement, nor suspending
or preventing the use of the Base Prospectus, the Prospectus or any Permitted Free Writing Prospectus, has been issued, and no proceeding
for that purpose has been instituted or, to the best of their knowledge, is contemplated by the Commission or any state or regulatory
body;


 


(iii)   The Shares to be sold on that date have been duly and validly authorized by the Company and all corporate action required
to be taken for the authorization, issuance and sale of the Shares on that date has been validly and sufficiently taken;


 


(iv)   Subsequent to the respective dates as of which information is given in the Base Prospectus, the Prospectus or any Permitted
Free Writing Prospectus, as amended and supplemented, and except for pending transactions disclosed therein, the Company has not incurred
any material liabilities or obligations, direct or contingent, or entered into any material transactions, not in the ordinary course of
business, or declared or paid any dividends or made any distribution of any kind with respect to its capital stock, and there has not
been any change in the capital stock or any issuance of options, warrants, convertible securities or other rights to purchase the capital
stock (other than as a result of the exercise of any currently outstanding options, warrants, preferred stock and notes that are disclosed
in the Registration Statement or the Prospectus or the issuance of securities pursuant to the Company's equity incentive plans or employee
stock purchase plans described in the Registration Statement or the Prospectus), or any material change in the short-term or long-term
debt, of the Company, or any Material Adverse Effect or any development that would reasonably be likely to result in a Material Adverse
Effect (whether or not arising in the ordinary course of business), or any material loss by strike, fire, flood, earthquake, accident
or other calamity, whether or not covered by insurance, incurred by the Company; and


 


(v)   Except as stated in the Prospectus and any Permitted Free Writing Prospectus, as amended and supplemented, there is not
pending, or, to the knowledge of the Company, threatened or contemplated, any action, suit or proceeding to which the Company is a party
before or by any court or governmental agency, authority or body, or any arbitrator, which would reasonably be likely to result in any
Material Adverse Effect;


 


provided, however, the requirement
to provide a certificate under this Section 3(s) is hereby waived for any Bringdown Date occurring at a time at which no Transaction
Notice is pending, which waiver shall continue until the earlier to occur of the date the Company delivers a Transaction Notice hereunder
and the next occurring Bringdown Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Bringdown
Date when the Company relied on such waiver and did not provide Agent with a certificate under this Section 3(s), then before the
Company delivers the Transaction Notice or Agent sells any Shares, the Company shall provide Agent with a certificate dated the date of
the Transaction Notice.


 


(t)  A
reasonable time prior to each Bringdown Date, the Company, if so requested by the Agent, shall conduct a due diligence session, in form
and substance, satisfactory to the Agent, which shall include representatives of the management and the accountants of the Company.


 






     


     


    

 


(u)  The
Company shall disclose in its annual report on Form 10-K and its quarterly reports on Form 10-Q the number of Shares sold through the
Agent under this Agreement, the Net Proceeds to the Company and the compensation paid by the Company with respect to sales of the Shares
pursuant to this Agreement.


 


(v)  The
Company shall ensure that there are at all times sufficient shares of Common Stock to provide for the issuance, free of any preemptive
rights, out of its authorized but unissued Common Stock, of the maximum aggregate number of Shares authorized for issuance by the Board
pursuant to the terms of this Agreement. The Company will use its reasonable best efforts to cause the Shares to be listed on the NASDAQ
Capital Market, and to maintain such listing. The Company shall cooperate with Agent and use its reasonable efforts to permit Shares to
be eligible for clearance and settlement through the facilities of DTC.


 


(w)  At
any time during the term of this Agreement, the Company will advise the Agent promptly after it receives notice or obtains knowledge of
any information or fact that would alter or affect any opinion, certificate, letter and other document provided to the Agent pursuant
to Section 3.


 


(x)   Subject
to compliance with any applicable requirements of Regulation M under the Exchange Act and compliance with applicable securities laws,
the Company consents to the Agent trading in the Common Stock for the Agent's own account and for the account of its clients (in compliance
with all applicable laws) at the same time as sales of the Shares occur pursuant to this Agreement.


 


(y)  If
to the knowledge of the Company, any condition set forth in Section 4 shall not have been satisfied on the applicable Settlement
Date or will not be satisfied on or prior to the date required by this Agreement, the Company will offer to any person who has agreed
to purchase the Shares on such Settlement Date from the Company as the result of an offer to purchase solicited by the Agent the right
to refuse to purchase and pay for such Shares.


 


(z)   On
or prior to the delivery of the first Transaction Notice issued hereunder and each Bringdown Date, the Company shall furnish to the Agent
an incumbency certificate, dated as of such date and addressed to Agent, signed by the secretary of the Company.


 


(aa)Each
acceptance by the Company of an offer to purchase the Shares hereunder shall be deemed to be an affirmation to the Agent that the representations
and warranties of the Company contained in or made pursuant to this Agreement are true and correct as of the date of such acceptance as
though made at and as of such date, and an undertaking that such representations and warranties will be true and correct as of the Settlement
Date for the Shares relating to such acceptance, as though made at and as of such date (except that such representations and warranties
shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented relating to such Shares).


 






     


     


    

 


(bb)During any period
when the delivery of a prospectus relating to the Shares is required (including in circumstances where such requirement may be satisfied
pursuant to Rule 172, 173 or any similar rule) to be delivered under the Securities Act, the Company will file all documents required
to be filed with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and the regulations
thereunder.


 


(cc)The Company shall
cooperate with Agent and use its reasonable efforts to permit the Shares to be eligible for clearance and settlement through the facilities
of DTC.


 


(dd)The Company will apply
the Net Proceeds from the sale of the Shares in the manner set forth in the Prospectus.


 


(ee)To the extent that
the Registration Statement is not available for the sales of the Shares as contemplated by this Agreement, the Company shall file a new
registration statement with respect to any additional shares of Common Stock necessary to complete such sales of the Shares and shall
cause such registration statement to become effective as promptly as practicable. After the effectiveness of any such registration statement,
all references to “Registration Statement” included in this Agreement shall be deemed to include such new registration statement,
including all documents incorporated by reference therein pursuant to Item 12 of Form S-3, and all references to “Base Prospectus”
included in this Agreement shall be deemed to include the final form of prospectus, including all documents incorporated therein by reference,
included in any such registration statement at the time such registration statement became effective.


 


4.
 Conditions of Agent's Obligations. The obligations
of the Agent hereunder are subject to (i) the accuracy of, as of the date hereof, each Bringdown Date, and each Time of Sale (in each
case, as if made at such date), and compliance with, all representations, warranties and agreements of the Company contained herein, (ii)
the performance by the Company of its obligations hereunder and (iii) the following additional conditions:


 


(a) If
filing of the Prospectus, or any amendment or supplement thereto, or any Permitted Free Writing Prospectus, is required under the Securities
Act or the Rules and Regulations, the Company shall have filed the Prospectus (or such amendment or supplement) or such Permitted Free
Writing Prospectus with the Commission in the manner and within the time period so required (without reliance on Rule 424(b)(8) or Rule
164(b)); the Registration Statement shall remain effective; no stop order suspending the effectiveness of the Registration Statement or
any part thereof, any Rule 462(b) Registration Statement, or any amendment thereof, nor suspending or preventing the use of the Base Prospectus,
the Prospectus or any Permitted Free Writing Prospectus shall have been issued; no proceedings for the issuance of such an order shall
have been initiated or threatened; and any request of the Commission for additional information (to be included in the Registration Statement,
the Base Prospectus, the Prospectus, any Permitted Free Writing Prospectus or otherwise) shall have been complied with to the Agent's
satisfaction.


 






     


     


    

 


(b)   The
Agent shall not have advised the Company that the Registration Statement, the Base Prospectus, the Prospectus, or any amendment or supplement
thereto, or any Permitted Free Writing Prospectus, contains an untrue statement of fact which, in the Agent's opinion, is material, or
omits to state a fact which, in the Agent's opinion, is material and is required to be stated therein or is necessary to make the statements
therein (i) with respect to the Registration Statement, not misleading and (ii) with respect to the Base Prospectus, the Prospectus or
any Permitted Free Writing Prospectus, in light of the circumstances under which they were made, not misleading.


 


(c)   Except
as set forth or contemplated in the Prospectus and any Permitted Free Writing Prospectus, subsequent to the respective dates as of which
information is given therein, the Company shall not have incurred any material liabilities or obligations, direct or contingent, or entered
into any material transactions, or declared or paid any dividends or made any distribution of any kind with respect to its capital stock
and there shall not have been any change in the capital stock, or any issuance of options, warrants, convertible securities or other rights
to purchase the capital stock (other than as a result of the exercise of any currently outstanding options, preferred stock, notes or
warrants that are disclosed in the Registration Statement or the Prospectus or the issuance of securities pursuant to the Company's equity
incentive plans or employee stock purchase plans described in the Registration Statement or the Prospectus), or any material change in
the short-term or long-term debt, of the Company, or any Material Adverse Effect or any development that would be reasonably likely to
result in a Material Adverse Effect (whether or not arising in the ordinary course of business), or any material loss by strike, fire,
flood, earthquake, accident or other calamity, whether or not covered by insurance, incurred by the Company, the effect of which, in any
such case described above, in the Agent's judgment, makes it impractical or inadvisable to offer or deliver the Shares.


 


(d)   The Company shall have performed each of its obligations under Section 3(q).


 


(e)   The
Company shall have performed each of its obligations under Section 3(r).


 






     


     


    

 


(f)    The Company shall have performed each of its obligations under Section 3(s).


 


(g)   FINRA
shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.


 


(h)   All
filings with the Commission required by Rule 424 under the Securities Act to have been filed by the Settlement Date shall have been made
within the applicable time period prescribed for such filing by Rule 424.


 


(i)    The
Company shall have furnished to Agent and the Agent's counsel such additional documents, certificates and evidence as they may have reasonably
requested.


 


(j)    Trading
in the Common Stock shall not have been suspended on the NASDAQ Capital Market.


 


All such opinions, certificates,
letters and other documents will be in compliance with the provisions hereof only if they are reasonably satisfactory in form and substance
to Agent and the Agent's counsel. The Company will furnish Agent with such conformed copies of such opinions, certificates, letters and
other documents as Agent shall reasonably request.


 


5.
Indemnification and Contribution.


 


(a)   The
Company agrees to indemnify and hold harmless the Agent and each of the other Indemnified Parties (as defined below) from and against
any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses and disbursements, and any and all
actions suits proceedings and investigations in respect thereof and any and all legal and other costs, expenses and disbursements in giving
testimony or furnishing documents in response to subpoena or otherwise (including, without limitation, the costs, expenses and disbursements,
as and when incurred, of investigating, preparing, pursuing or defending any such action, suit, proceeding or investigation (whether or
not in connection with litigation in which any Indemnified Party is a party)) (collectively, "Losses"), directly
or indirectly, caused by, relating to, based upon, arising out of, or in connection with this Agreement, including, without limitation,
any act or omission by the Agent in connection with its acceptance of or the performance or non-performance of its obligations under the
Agreement, any breach by the Company of any representation, warranty, covenant or agreement contained in the Agreement (or in any instrument,
document or agreement relating thereto, including any agency agreement), or the enforcement by the Agent of its rights under the Agreement
or these indemnification provisions, except to the extent that any such Losses are found in a final judgment by a court of competent jurisdiction
(not subject to further appeal) to have resulted primarily and directly from the gross negligence or willful misconduct of the Indemnified
Party seeking indemnification hereunder. The Company also agrees that no Indemnified Party shall have any liability (whether direct or
indirect, in contract or tort or otherwise) to the Company for or in connection with this Agreement for any other reason, except to the
extent that any such liability is found in a final judgment by a court of competent jurisdiction (not subject to further appeal) to have
resulted primarily and directly from such Indemnified Party's gross negligence or willful misconduct This indemnity agreement will be
in addition to any liability that the Company otherwise might have.


 






     


     


    

 


(i)
  These indemnification provisions shall extend to the following
persons (collectively, the "Indemnified Parties"): the Agent, its present and former affiliated entities, managers,
members, officers, employees, legal counsel, agents and controlling persons (within the meaning of the federal securities laws), and the
officers, directors, partners, stockholders, members, managers, employees, legal counsel, agents and controlling persons of any of them.
These indemnification provisions shall be in addition to any liability which the Company may otherwise have to any Indemnified Party.


 


(ii)
 If any action, suit, proceeding or investigation is commenced,
as to which an Indemnified Party proposes to demand indemnification, it shall notify the Company with reasonable promptness; provided,
however, that any failure by an Indemnified Party to notify the Company shall not relieve the Company from its obligations hereunder
except to the extent that the Company is actually and materially prejudiced by such failure to notify. An Indemnified Party shall have
the right to retain counsel of its own choice to represent it, and the fees, expenses and disbursements of such counsel shall be borne
by the Company. Any such counsel shall, to the extent consistent with its professional responsibilities, cooperate with the Company and
any counsel designated by the Company. The Company shall be liable for any settlement of any claim against any Indemnified Party made
with the Company's written consent. The Company shall not, without the prior written consent of the Agent, settle or compromise any claim,
or permit a default or consent to the entry of any judgment in respect thereof, unless such settlement, compromise or consent (i) includes,
as an unconditional term thereof, the giving by the claimant to all of the Indemnified Parties of an unconditional release from all liability
in respect of such claim, and (ii) does not contain any factual or legal admission by or with respect to an Indemnified Party or an adverse
statement with respect to the character, professionalism, expertise or reputation of any Indemnified Party or any action or inaction of
any Indemnified Party.


 


(iii)  In
order to provide for just and equitable contribution, if a claim for indemnification pursuant to these indemnification provisions is made
but it is found in a final judgment by a court of competent jurisdiction (not subject to further appeal) that such indemnification may
not be enforced in such case, even though the express provisions hereof provide for indemnification in such case, then the Company shall
contribute to the Losses to which any Indemnified Party may be subject (i) in accordance with the relative benefits received by the Company
and its stockholders, Subsidiaries and affiliates, on the one hand, and the Indemnified Party, on the other hand, and (ii) if (and only
if) the allocation provided in clause (i) of this sentence is not permitted by applicable law, in such proportion as to reflect not only
the relative benefits, but also the relative fault of the Company, on the one hand, and the Indemnified Party, on the other hand, in connection
with the statements, acts or omissions which resulted in such Losses as well as any relevant equitable considerations. No person found
liable for a fraudulent misrepresentation shall be entitled to contribution from any person who is not also found liable for fraudulent
misrepresentation. The relative benefits received (or anticipated to be received) by the Company and its stockholders, Subsidiaries and
affiliates shall be deemed to be equal to the aggregate consideration payable or receivable by such parties in connection with the transaction
or transactions to which the Agreement relates relative to the amount of fees actually received by the Agent in connection with such transaction
or transactions. Notwithstanding the foregoing, in no event shall the amount contributed by all Indemnified Parties exceed the amount
of fees previously received by the Agent pursuant to the Agreement.


 






     


     


    

 


(b) (i)
The Agent will indemnify and hold harmless the Company and its affiliates and directors and each officer of the Company who signed the
Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act (the "Company Indemnified Parties") from and against any Losses to which the Company or
the Company Indemnified Parties may become subject, under the Securities Act or otherwise (including in settlement of any litigation,
if such settlement is effected with the written consent of the Agent), insofar as such losses, claims, damages or liabilities (or actions
in respect thereof) arise out of or are based upon an untrue statement or omission or alleged untrue statement or omission of a material
fact contained in the Registration Statement, any Base Prospectus, the Prospectus, or any amendment or supplement thereto or any Permitted
Free Writing Prospectus, to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made
in the Registration Statement, any Base Prospectus, the Prospectus, or any amendment or supplement thereto, or any Permitted Free Writing
Prospectus in reliance upon and in conformity with written information furnished to the Company by Agent expressly for use in the preparation
thereof, it being understood and agreed that the only information furnished by the Agent consists of the information described as such
in Section 5(b)(ii), by the Company in connection with investigating or defending against any such loss, claim, damage, liability
or action. (ii) The Agent confirms and the Company acknowledges that as of the date hereof no information
has been furnished in writing to the Company by or on behalf of the Agent specifically for inclusion in the Registration Statement, any
Base Prospectus, the Prospectus or any Permitted Free Writing Prospectus, other than information about the Agent included in the Prospectus
Supplement under the heading "Plan of Distribution".


 


(c)  If
the indemnification provided for in this Section 5 is unavailable or insufficient to hold harmless an indemnified party under subsection
(a) or (b) above, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of
the losses, claims, damages or liabilities referred to in subsection (a) or (b) above, (i) in such proportion as is appropriate to reflect
the relative benefits received by the Company on the one hand and the Agent on the other from the Offering or (ii) if the allocation provided
by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i) above but also the relative fault of the Company on the one hand and the Agent on the other in connection with
the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations.
The relative benefits received by the Company on the one hand and the Agent on the other shall be deemed to be in the same proportion
as the total net proceeds from the Offering (before deducting expenses) received by the Company and the total underwriting discounts and
commissions received by the Agent, bear to the total public offering price of the Shares. The relative fault shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by the Company or the Agent and the parties' relevant intent, knowledge, access to information
and opportunity to correct or prevent such untrue statement or omission. The Company and the Agent agree that it would not be just and
equitable if contributions pursuant to this subsection (c) were to be determined by pro rata allocation or by any other method of allocation
which does not take account of the equitable considerations referred to in the first sentence of this subsection (c). The amount paid
by an indemnified party as a result of the losses, claims, damages or liabilities referred to in the first sentence of this subsection
(c) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating
or defending against any action or claim which is the subject of this subsection (c). Notwithstanding the provisions of this subsection
(c), the Agent shall not be required to contribute any amount in excess of the amount by which the total price at which the Shares underwritten
by it and distributed to the public were offered to the public exceeds the amount of any damages that the Agent has otherwise been required
to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation.


 






     


     


    

 


(d)   Neither
the termination of this Agreement nor completion of the Offering shall affect these indemnification provisions, which shall remain operative
and in full force and effect. The indemnification provisions shall be binding upon the Company and the Agent and their respective successors
and assigns and shall inure to the benefit of the Indemnified Parties and the Company Indemnified Parties and their respective successors,
assigns, heirs and personal representatives.


 


6.  Representations
and Agreements to Survive Delivery. All representations and warranties of the Company herein or in certificates delivered pursuant
hereto, and agreements of the Agent and the Company herein, including but not limited to the agreements of the Agent and the Company contained
in Section 5, shall remain operative and in full force and effect regardless of any investigation made by or on behalf of the Agent
or any controlling person thereof, or the Company or any of its officers, directors, or controlling persons, and shall survive delivery
of, and payment for, the Shares to and by the Agent hereunder.


 


7.
Termination of this Agreement. The term of this Agreement shall begin on the date hereof, and shall continue until the earlier
of (i) the sale of Shares having an aggregate offering price of $2,700,000, or (ii) the termination by either the Agent or the Company
upon the provision of fifteen (15) days written notice. Any such termination by mutual agreement shall in all cases be deemed to provide
that Section 3(g), Section 5 and Section 6 shall remain in full force and effect. Notwithstanding the foregoing,
the Agent shall have the right, in its sole discretion, to terminate this Agreement if at any time from the date of this Agreement to
the effectiveness of the Registration Statement, the Agent is not fully satisfied, in its sole discretion, with the results of its and
its representatives' review of the Company and the Company's business.


 


8.
Default by the Company. If the Company shall fail at any Settlement Date to sell and deliver the number of Shares which
it is obligated to sell hereunder, then this Agreement shall terminate without any liability on the part of the Agent or, except as provided
in Section 3(g), any non-defaulting party. No action taken pursuant to this Section 8 shall relieve the Company from liability,
if any, in respect of such default, and the Company shall (A) hold the Agent harmless against any loss, claim or damage arising from or
as a result of such default by the Company and (B) pay the Agent any commission to which it would otherwise be entitled absent such default.


 


9.
Notices. Except as otherwise provided herein, all communications
under this Agreement shall be in writing and, if to the Agent, shall be mailed, delivered or telecopied to Maxim Group LLC, 300 Park Avenue,
16th Floor, New York, New York 10022, Attention: Clifford A. Teller and James Siegel, with a required copy (which shall not
constitute notice) to Ellenoff Grossman & Schole LLP, counsel for the Agent, at 1345 Avenue of the Americas, New York, New York 10105
Attention: Sarah Williams, Esq. Notices to the Company shall be given to it at 2150 Cabot Blvd West, Suite B, Langhorne, PA 19047
Attention: Adam Levy, with required copies (which shall not constitute notice)
to Quick Law Group, P.C., 1035 Pearl Street, Suite 403 Boulder, CO 80302 Attention: Jeffrey Quick, Esq.. Any party to this Agreement may
change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose.


 






     


     


    

 


10.
Persons Entitled to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto
and their respective successors and assigns and the controlling persons, officers and directors referred to in Section 5. Nothing
in this Agreement is intended or shall be construed to give to any other person, firm or corporation any legal or equitable remedy or
claim under or in respect of this Agreement or any provision herein contained. The term "successors and assigns" as herein used
shall not include any purchaser, as such purchaser, of any of the Shares from the Agent.


 


11.
Absence of Fiduciary Relationship. The Company acknowledges and agrees that: (a) the Agent has been retained solely to act
as an sales agent and/or principal in connection with the sale of the Shares and that no fiduciary, advisory or agency relationship between
the Company and the Agent has been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether
the Agent has advised or are advising the Company on other matters; (b) the price and other terms of the Shares set forth in this Agreement
were established by the Company following discussions and arms-length negotiations with the Agent and the Company is capable of evaluating
and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated by this Agreement; (c)
it has been advised that the Agent and its affiliates are engaged in a broad range of transactions which may involve interests that differ
from those of the Company and that the Agent has no obligation to disclose such interest and transactions to the Company by virtue of
any fiduciary, advisory or agency relationship; (d) it has been advised that the Agent is acting, in respect of the transactions contemplated
by this Agreement, solely for the benefit of the Agent, and not on behalf of the Company; and (e) it waives to the fullest extent permitted
by law, any claims it may have against the Agent for breach of fiduciary duty or alleged breach of fiduciary duty in respect of any of
the transactions contemplated by this Agreement and agrees that the Agent shall have no liability (whether direct or indirect) to the
Company in respect of such a fiduciary duty claim on behalf of or in right of the Company, including stockholders, employees or creditors
of the Company.


 


12.
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, including
Section 5-1401 of the General Obligations Law of the State of New York, but otherwise without regard to conflict of laws rules that would
apply the laws of any other jurisdiction.


 


13.
Counterparts. This Agreement may be executed in one or more counterparts and, if executed in more than one counterpart,
the executed counterparts shall each be deemed to be an original and all such counterparts shall together constitute one and the same
instrument.


 


14.
Adjustments for Stock Splits. The parties acknowledge and agree that all share-related numbers contained in this Agreement
shall be adjusted to take into account any stock split, stock dividend or similar event effected with respect to the Shares.


 


15.
Entire Agreement; Amendment; Severability; Headings. This Agreement (including all schedules and exhibits attached hereto
and transaction notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements
and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor
any term hereof may be amended except pursuant to a written instrument executed by the Company and the Agent. In the event that any one
or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable
as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent
that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal
or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder
of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement. The section headings
used in this Agreement are for convenience only and shall not affect the construction hereof.


 


16.
Waiver of Jury Trial. Each of the Company and the Agent hereby waives any right it may have to a trial by jury in respect
of any claim based upon or arising out of this Agreement or the transactions contemplated hereby.


 




     


     


    


 


  


 


Please sign and return to the Company the enclosed
duplicates of this letter whereupon this letter will become a binding agreement between the Company and the Agent in accordance with its
terms.


 


Very truly yours, 



NEXGEL, INC.



 


	By:	 /s/ Adam Levy	 


Name: Adam Levy

Title: Chief Executive Officer


 


MAXIM GROUP LLC


 





	By:	/s/ Clifford Teller	 


Name: Clifford Teller

Title: Executive Managing Director & Head of Investment Banking.


 




     


     


    


 


 


 


 


Schedule A


 


Permitted Free Writing Prospectus


 


None.


 


 


 


 


 


 




     


     


    


 


 


 


 


 


Schedule B


 


Individuals Permitted to Authorize Sales of Shares 


Adam Levy


Adam E. Drapczuk III


 


 


 


 


 




     


     


    


 


 


Schedule C


 


Form of E-mail or Telecopy Confirmation


 


[COMPANY LETTERHEAD]


 


 


Date: ______________


 


Maxim Group LLC


300 Park Ave, 16th Floor

New York, NY 10022


Attn:


 


RE: E-mail Confirmation to Sell Stock Utilizing the Equity Distribution
Agreement


 


Maxim Equity Trading Team:


 


Pursuant to the terms and subject to the conditions
contained in the Equity Distribution Agreement between NexGel, Inc. (the "Company") and Maxim Group LLC ("Maxim")
dated April 13, 2022 (the "Agreement"), we hereby confirm our request by e-mail transmission on behalf of the
Company that Maxim is authorized to sell for a period of up to _________ business days, up to ______________ shares of the Company's Common
Stock at a minimum market price of $________ per share.


 


Thanks for all your help and please contact us
with any questions,


 


Sincerely,


 


NexGel, Inc.


 


	 	 



By:


Name:


 


 




     


     


    


 


 


Schedule D


 


Individuals to Which Notice Can Be Given


 


For Maxim Group LLC:


 


Cliff Teller


Brad Hoffman


Michael Quintavalla


Joe Daneshgar




For NexGel, Inc.:


 


Adam Levy


Adam E. Drapczuk III